Business
Alligator Bioscience Announces that 85% of the Warrant Programme TO 12 has Been Secured and that the Outstanding Loan has Been Renegotiated
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH ...
About this update from Alligator Bioscience Ab
[{"type":"text","content":"NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE.","length":355,"tagName":"p"},{"type":"text","content":"LUND, SWEDEN / ACCESS Newswire / May 9, 2025 / Alligator Bioscience (STO:ATORX)("Alligator Bioscience" or the "Company") hereby announces that the Company has received undertakings corresponding to 85 per cent of the outstanding warrants series TO 12 ("TO 12") (the "Warrant Programme"). The Company has received subscription undertakings from the Company's Chairman of the Board of Directors, CEO and CFO as well as several larger and smaller holders of TO 12, including Roxette Photo SA, amounting in total to approximately SEK 16.2 million and corresponding to approximately 22.4 per cent of the Warrant Programme (the "Subscription Undertakings"). In addition to the Subscription Undertakings, the Company has received guarantee undertakings from existing holders of TO 12 and external investors in the form of so-called top and bottom guarantees amounting to approximately SEK 45.4 million, corresponding to approximately 62.7 per cent of the Warrant Programme (the "Guarantee Undertakings"). The Company has also received a subscription intention amounting up to SEK 3 million from one of the Company's larger shareholders, where such intention is not included in the guarantee structure. The Guarantee Undertakings will be utilized in case the subscription of ordinary shares in the Warrant Programme is below approximately 85 per cent. The exercise period for TO 12 runs up to and including 19 May 2025. The last day of trading in TO 12 is 15 May 2025. In connection with the above, Alligator Bioscience has also renegotiated the outstanding loan from Fenja Capital II A/S ("Fenja Capital"), which originally was raised in June 2024 and subsequently renegotiated in December 2024.","length":1766,"tagName":"p"},{"type":"text","content":"Søren Bregenholt, CEO of Alligator Bioscience, comments:","length":56,"tagName":"p"},{"type":"blockquote","items":[{"val":[{"type":"text...